ALL
-
-
Jul 19, 2023 product/service
-
-
product/service
-
Notice Regarding Approval of Partial Amendments to Indications, Dosage and Administration of ROSUVASTATIN TABLETS 2.5mg/5mg “KYOSOMIRAI”, ROSUVASTATIN OD TABLETS 2.5mg/5mg “KYOSOMIRAI”, ROSUVASTATIN TABLETS 2.5mg/5mg “KMP”, ROSUVASTATIN OD TABLETS 2.5mg/5mg “KMP” for KYOSOMIRAI PHARMA(117 KB)
-
-
Jun 29, 2023 corporate
-
-
corporate
-
Notice Regarding Executive Appointment(121 KB)
-
-
Jun 16, 2023 product/service
-
-
product/service
-
Notice Regarding Launch of 1 Ingredient / 3 Products of Generic Drugs for KYOSOMIRAI PHARMA(111 KB)
-
-
Jun 16, 2023 product/service
-
-
product/service
-
Notice Regarding Change of Trade Names for 5 Ingredients and 11 Products Manufactured and Sold by the Company(110 KB)
-
-
Jun 14, 2023 other
-
-
other
-
Our view on proxy voting recommendations made by ISS(191 KB)
-
-
May 17, 2023 product/service
-
-
product/service
-
Notice Regarding Approval of Partial Amendments to Dosage and Administration of Donepezil Hydrochloride Tablets 3mg / 5mg / 10mg “FFP” and Donepezil Hydrochloride OD Tablets 3mg / 5mg / 10mg “FFP” for KYOSOMIRAI PHARMA(160 KB)
-
-
May 17, 2023 other
-
-
other
-
Medium-term Management Plan 2023-2025 “Create the Next Generation”(3 MB)
-
-
May 12, 2023 other
-
-
other
-
Notice Regarding formulation the Medium-term Management Plan 2023-2025 “Create the Next Generation”(172 KB)
-
-
May 12, 2023 performance
-
-
performance
-
Consolidated Financial Results for the Fiscal Year Ended March 31, 2023(536 KB)
-
-
May 12, 2023 other
-
-
other
-
Notice Regarding Daizawa Project(160 KB)
-
-
May 12, 2023 stock
-
-
stock
-
Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2023(79 KB)
-
-
May 12, 2023 corporate
-
-
corporate
-
Notice Regarding Decision on the Candidates for Directors(111 KB)
-
-
Mar 24, 2023 other
-
-
other
-
Notice Regarding Cease and Desist Order and Surcharge Payment Order from the Japan Fair Trade Commission(70 KB)
-
-
Feb 09, 2023 performance
-
-
performance
-
Consolidated Financial Results for the Nine Months Ended December 31, 2022(365 KB)
